The staphylococcal scalded-skin syndrome is represented by a spectrum of clinical entities that include: a generalized exfoliative dermatitis (Ritter's disease, toxic epidermal necrolysis), bullous impetigo, and a scarlatiniform rash (15). The majority of clinical reports of the disease have emphasized the occurrence of disease primarily in infants and children (15). Initially this age-related susceptibility also appeared to apply to the mouse model described by Melish and Glasgow (14). Subsequently, a small number of cases has been reported in human adults (3-5, 10, 11, 16, 19). In the majority of these cases in adults, with the exception of those reported by Epstein and co-workers (5), some predisposing factor or underlying disease, such as alcoholism, immunosuppression, or compromised cell-mediated immunity was present and may have played a role in the development of the disease. The susceptibility of adult skin to the action of the exfoliative toxin (ET) in both humans (3, 24) and experimental animals (4) has now been demonstrated convincingly. These data suggest that the relatively low incidence of dermatological manifestations of phage group II staphylococcal infection may be related to the presence of antibody (antitoxin) that is capable of neutralizing the toxin responsible for the exfoliation of the superficial layer of the epidermis. The purpose of this report is to describe the development of a radioimmunobinding assay for the ET and to present initial data concerning: (i) the frequency of occurrence of antibody to ET in the general population, (ii) the incidence of antibody correlated with age, (iii) the presence of antibody in patients with scalded-skin syndrome, and (iv) the sensitivity of the radioimmunobinding assay compared with the in vitro neutralization assay.
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MATERIALS AND METHODS
Cultures. The ET used in this study was produced in vitro from the UT 0002 strain of Staphylococcus aureus, a previously (17) described phage group II isolate that was grown in heart infusion broth (HIB, Difco) on a gyratory water bath shaker with a gas hood (New Brunswick Scientific Co.). Cultures were grown in 100-ml amounts in 250-ml screw-capped Counting of radioactivity. Gamma disintegrations were counted on a Beckman Biogamma counter with an 125I isoset. The radioimmunobinding tests were carried out in glass disposable tubes (10 by 60 mm) with parafilm caps. This permitted their accommodation into the Beckman Biogamma plastic counting vials. Since the vials were not in contact with the actual radioactivity, they could be reused.
Tests were set up in duplicate, and 50 Al of supernatant fluid was counted for 20 min in the antigenbinding assays. Controls consisted of antigen plus normal human serum diluted 1:40 in TS-BSA. The error of the count was 3%, and the counting efficiency for '25I in the instrument was 86%.
Titration of biological activity of ET. Swiss Webster mice less than 5 days old were randomized and injected intracutaneously in the scapular region with 0.05 ml of a dilution of the ET preparation being titered. Ten mice per dilution were used, and mice were examined 18 h after injection for evidence of a positive Nikolsky sign as an indication of exfoliative activity. Biological activity was expressed as exfoliative units per milliliter or units per milligram of protein defined as the reciprocal of the highest dilution of ET that produced a positive Nikolsky sign in 50% of the mice after 18 h.
Immunization. Young, 5-to 7-lb (ca. 2.27 to 3.18 kg) New Zealand white rabbits were immunized with purified electrofocused ET over a period of 1 year. Three initial injections of 100 ,ug each were given intravenously; then subsequent injections were given intramuscularly in Freund complete adjuvant until a total of 5 mg of ET protein had been injected. Animals were bled weekly from a marginal ear vein, and the serum was separated from the clot after standing at 4 C for 18 h. RESULTS S. aureus strain UT 0002 regularly yielded crude toxin preparations with 20,000 exfoliating units/ml when cultured on a shaker in HIB flushed periodically with 100% CO2. Electrofocusing of these crude ET preparations usually
on November 2, 2017 by guest http://iai.asm.org/ Downloaded from yielded a preparation with 2,000 to 10,000 units/ml or 3,000 to 10,000 units/mg of protein.
The mean molecular weights of the focused preparations were 32,400 ± 3,100, based on 10 different preparations. Polyacrylamide gel electrophoresis of the focused preparations in amounts of 15, 30, or 60 ,ug of protein regularly exhibited single bands after staining with Coomassie blue (Fig. 1 ). Since only a single protein appeared to be present, even when 60 jpg of ET protein was electrophoresed, an attempt was made to radioiodinate the ET. A radioactive ET with a specific activity of 0.013 ,LCi/,ug was obtained by using the procedure of Marchalonis (13) . A variety of precipitating agents were tried to test the precipitability of the labeled ET to provide us with data concerning the quantity of unbound label. Our first experiments indicated only about 40% of the labeled ET could be precipitated by 10 or 20% aqueous trichloroacetic acid, even though the labeled ET had been subjected to column chromatography to free it of unbound 125I. A variety of precipitants were added to portions of ET, and the mixtures were left at 4 C for 18 h, followed by centrifugation for 30 min at 4 C at 2,500 x g in a Beckman J-21 refrigerated centrifuge with a JS-13 rotor. A 100-pu1 portion of the supernatant fluid from the precipitations was removed and counted in a Biogamma counter. gl per 20 min. Antigen was diluted in the TS-BSA, and the rabbit anti-serum was diluted in normal rabbit serum 1:40 in TS-BSA. Initial tests using goat anti-7S rabbit globulin (Hyland) produced disappointingly low titers and were expensive to carry out since the antiglobulin had to be used at a low dilution. Subsequently, it was ascertained that the Farr (7) technique could be utilized to precipitate the antigen-antibody complexes. Preliminary experiments showed that addition of aqueous, icecold saturated (NH4)2S04 to a final concentration of 50% precipitated the bound, but not the unbound, ET. The antigen-binding assay was set up as follows: rabbit antiserum dilutions in 1:40 normal rabbit serum, 25 jul, and '251-labeled ET diluted to 33 counts/! l per min in TS-BSA, 25 ,ul, were added to disposable glass tubes (10 by 60 mm), and the reactants were mixed on a Vortex mixer. The tubes were capped with parafilm and incubated at 37 C for 2 h, followed by 4 C for 18 h. To each tube was then added 50 Al of ice-cold, aqueous saturated was previously described (24) . Unfortunately, in most instances only a convalescent serum was available for testing. Ages of the patients varied from 1 month to over 70 years. Titers are shown as the reciprocal of the highest final dilution of serum that bound at least 10% of the radiolabeled ET. It was considered that antigen further diluted the initial dilution of antiserum twofold. A group of sera from 64 randomly chosen patients of all ages from less than 1 year to 69 years was next tested by the primary antigen-binding test. The results of these assays are shown in Fig. 3 . They ranged from sera with titers of less than 4 to one that had a titer of 128. No particular age distribution of either negatives (titers less than 4) or positives (titers of 4 and two hyperimmune rabbits (R3 and R4) under immunization for over 1 year with electrofocused ET. The last three sera were tested with a final concentration of 5 ET units. There was good correlation between neutralizing titers, binding titers, and antitoxin content of the sera. The least sensitive method of measuring anti-ET was in the in vitro neutralization test. The primary antigen-binding test using 125I1 labeled ET was much more sensitive as a detector of anti-ET. Differences in antitoxin content of the sera reflect the differing amounts of ET used in the neutralization tests; thus, "normal" human serum K.O. neutralized 5 units of ET at a dilution of 1:4 and, hence, it contained more antitoxin than serum B.W., which neutralized only 2.5 units of ET.
DISCUSSION
It appears that we successfully radioiodinated the purified ET used in the work described here. An experiment to assure that binding of '25I-labeled ET was specific was first carried out using purified human Fc fragment from immunoglobulin G. It is known that protein A in S. aureus non-specifically combines with the Fc portion of human or rabbit immunoglobulin G so, if our ET preparation had contained contaminating protein A, we might have obtained nonspecific binding of the INFECT. IMMUN. labeled ET. There was no evidence of binding of our '25I-labeled ET preparation by purified Fc fragment; hence this possibility was ruled out. Inhibition tests further revealed that the reaction was specific by showing that 372 ng of unlabeled ET significantly inhibited the reaction between 125I-labeled ET and rabbit antibody to ET.
Patients with confirmed staphylococcal scalded-skin syndrome do have detectable antibody to staphylococcal ET. Two confirmed cases, F.T. and Mrs. T, had elevated titers of anti-ET compared with most of the other patients in our series. One normal subject (mother L) also had an elevated antibody titer. Certainly, randomly chosen subjects also have antibody to ET in amounts comparable to many of the patients with confirmed staphylococcal scalded-skin syndrome. In our series of 64 randomly chosen subjects, no differences between adults and children regarding antibody to ET were discernible. Since staphylococcal carriage averages around 50% (23) and since phage group II strains comprise up to 11% of staphylococcal strains (22), it is not surprising that a high percentage of humans has antibody to ET. The presence of antibodies to ET in the serum of the two babies in our series of patients could have been the result of transplacental transfer of maternal antibodies since they had amounts similar to those of their mothers. It was to be expected that an assay based on use of a radioactive tracer for detecting soluble antigen-antibody complexes would be more sensitive than one based on precipitation of the antigen. The experience of Brunner and Chanock (2) revealed that a radioimmunoprecipitation test was more sensitive than complement fixation, immunofluorescence, or metabolic inhibition tests in detecting antibody to Mycoplasma pneumoniae in human sera. Our test was reproducible in that, when sera were tested on separate days, titers did not differ more than twofold. The increased sensitivity of our primary antigen-binding test was possible because the actual amount of protein used in the antigen-binding assay was 71.5 ng, which represented one-fourth of a mouse exfoliating unit of ET. The maximum binding of radioiodinated antigen in our tests was not as high as that reported by Brunner and Chanock (2) . The maximum binding detected in our system was in the 30 to 40% range, whereas Brunner and Chanock (2) reported binding of 80% of their labeled mycoplasma antigen. Previously we reported the possibility of the ET being a glycoprotein (18 On the other hand both the labeled ET and the antiserum may be responsible for the low binding capacity in our system. If the quantity of antibody is limited and if only a portion of the ET molecules are actually labeled, then one could account for the binding percentages we obtained on the basis of competition of labeled and unlabeled ET for the limited antibody binding sites. Alternatively, the labeling procedure may have immunologically altered the ET molecules in such a way that only a portion of them now react with the antibody produced against purified unlabeled ET. Bolton and Hunter (1) reported loss of immunoreactivity of humanluteinizing hormone when labeled by the chloramine T procedure of Greenwood et al. (9) , as compared with a labeling procedure they developed in which the protein being labeled is not directly exposed to the 125I solution or reagents used in the iodination. We tried to more efficiently trap the antigen-antibody complexes by employing normal serum at 1:8 instead of 1:40, reasoning that a more voluminous precipitate of globulins after addition of the saturated (NH4)2SO4 would more efficiently trap the complexes. The higher concentration of normal serum, however, did not result in higher binding of labeled ET.
From a consideration of the specific activities of radiolabeled antigens employed by others (1, 2, 9), it must be concluded that our radioiodinated antigen had low specific activity. Without an amino acid analysis, we do not know whether this low specific activity was the result of insufficient iodination or a low content of tyrosine and histidine in the ET. We hope to solve this problem by attempting to raise the titer of antibodies in our animals and to increase the specific activity of the ET by utilizing more rigorous iodination. As to whether antitoxin plays a definitive role in host resistance, one must consider that the lesions in staphylococcal scalded-skin syndrome may be at a site distant from the site of infection; hence, ET may be transported via the circulation to epidermal target cells. In other instances, e.g., bullous impetigo, the toxin is produced locally and may act locally. At the present time we do not have the capability of detecting free ET in plasma or the fluid of bullae. In our culture system, some phage group II staphylococci, especially those with an ET plasmid, regularly elaborate over 20,000 mouse exfoliating units of toxin per ml of culture in 18 h. One could reasonably postulate that cultivation in artificial medium represents only an approximation of the in vivo conditions; hence, large amounts of toxin may be produced in patients with staphylococcal scalded-skin syndrome. If this postulation is reasonable, then large amounts of antitoxin might be necessary to neutralize the ET sufficiently to prevent exfoliation. Even our hyperimmune rabbit serum neutralized only 5 units of toxin and a dilution of only 1:16. It does not seem likely, therefore, that the ET antibody in the amounts detected in our neutralization tests could explain host resistance to the staphylococcal scalded-skin syndrome. In a previous paper (24), we showed that immunosuppression did not affect susceptibility of suckling mice to the isolated ET but that it increased their susceptibility to infection by toxigenic strains of S. aureus, allowing development of the scaldedskin syndrome from smaller inocula of organisms. These data indicate that antibacterial factors clearly are determinants of host resistance in the mouse model and suggest that a similar situation may occur in humans. Half of the subjects in the proven cases of staphylococcal scalded-skin syndrome had compromising conditions at the time of development of the disease. These included immunosuppression, diabetes, presence of neoplastic disease, and possible immunological immaturity. Other workers described cases of staphylococcal scalded-skin syndrome in compromised adults (10, 11, 16, 19) . The relatively low incidence of this syndrome may be due to failure to recognize it in its protean manifestations or to a VOL. 13, 1976 requirement that depressed host defenses be present to allow initiation of infection in most adults.
